Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination
Jinyi Tang,Cong Zeng,Thomas M. Cox,Chaofan Li,Young Min Son,In Su Cheon,Yue Wu,Supriya Behl,Justin J. Taylor,Rana Chakaraborty,Aaron J. Johnson,Dante N Shiavo,James P. Utz,Janani S. Reisenauer,David E. Midthun,John J. Mullon,Eric S. Edell,Mohamad G. Alameh,Larry Borish,Mark H. Kaplan,Drew Weissman,Ryan Kern,Haitao Hu,Robert Vassallo,Shan-Lu Liu,Jie Sun
DOI: https://doi.org/10.1101/2022.01.26.22269659
2022-01-27
Abstract:Abstract SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S-specific total and neutralizing antibody (Ab) responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19 vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing Ab against D614G, Delta and Omicron in the BAL compared to COVID-19 convalescents, despite robust S-specific Ab responses in the blood. Further, mRNA vaccination induced significant circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using an animal immunization model, we demonstrate that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing Ab responses, especially against SARS-CoV-2 Omicron; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing Ab response, not only against the ancestral virus but also the Omicron variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during re-infection, but offer limited protection against breakthrough infection, especially by Omicron. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by Omicron and future variants.